Duration of Response With Xevinapant Plus Standard Chemoradiation in LA SCCHN

Jean Bourhis, MD, a professor of radiation oncology at the University of Paris, discusses results from the phase 2 study of xevinapant plus chemoradiation vs placebo and chemoradiation in patient with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN; NCT02022098).

Results from the 5-year analysis of the study were presented during the European Society of Medical Oncology Congress 2022 by Bourhis. It was shown that the addition of xevinapant to standard-of-care chemoradiation improved the durability of responses in patients with LA SCCHN.

Transcript:

0:08 | The study was a phase 2 randomized trial comparing placebo versus xevinapant with standard of care in patients with locally advanced from cell carcinoma the head and neck. These patients were really high-risk patients, the most advanced among the locally advanced cases. And we knew already that xevinapant was active and well tolerated in the same study. tThe results that we presented [at ESMO] are long-term follow up results. And especially we have data here on overall survival at 5 years, which we didn't have before.

1:03 | What do we see here in this study with long-term follow up the 5-year overall survival is markedly improved with the xevinapant when compared to placebo. And there is nearly a doubling of the overall survival at 5 years. The data [shows that] it's from 28%, with placebo to 53% with xevinapant and we can say that in this selection of patients, again with really high-risk, locally advanced squamous cell cancer of the head and neck. This is something we've never seen in the last 3 decades because the standard of care, cisplatin radiotherapy, has never been improved with the new treatme